OncoMatch/Clinical Trials/NCT03681561
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Is NCT03681561 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Ruxolitinib and Nivolumab for hodgkin lymphoma.
Treatment: Ruxolitinib · Nivolumab — This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: checkpoint inhibitor (nivolumab, pembrolizumab)
Prior therapy with check-point inhibitors (nivolumab, pembrolizumab, others) and subsequent progressive disease, stable disease, mixed response, or relapse
Lab requirements
Blood counts
Absolute Neutrophil Count ≥ 1000/μL; Platelets ≥ 75,000/μL (or ≥50,000/mm3 if known BM involvement)
Kidney function
Calculated creatinine clearance ≥ 40 cc/min using the Cockcroft-Gault formula
Liver function
Bilirubin ≤ 1.5 x upper limit of normal (ULN); AST ≤ 2.5 × ULN; ALT ≤ 2.5 × ULN
Absolute Neutrophil Count ≥ 1000/μL; Platelets ≥ 75,000/μL (or ≥50,000/mm3 if known BM involvement); Calculated creatinine clearance ≥ 40 cc/min using the Cockcroft-Gault formula; Bilirubin ≤ 1.5 x upper limit of normal (ULN); AST ≤ 2.5 × ULN; ALT ≤ 2.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Illinois Cancer Center · Chicago, Illinois
- Indiana Melvin and Bren Simon Comprehensive Cancer Center · Indianapolis, Indiana
- University of Iowa Hospitals and Clinics · Iowa City, Iowa
- University of Minnesota · Minneapolis, Minnesota
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03681561 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received checkpoint inhibitor.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages